Precigen has earned a STRONG BUY rating due to the commercial success of its drug PAPZIMEOS, now approved as a first-line therapy for recurrent respiratory papillomatosis (RRP) and covered by major US insurers. The company's AdenoVerse platform supports a scalable business model, and management expects to reach cash flow breakeven by 2026. Despite competition risks from INO-3107, Precigen's strong commercial momentum and recent Wall Street upgrades to earnings and revenue forecasts highlight its growth potential.
AI/R Compass UOL, a subsidiary of AI/R specializing in Agentic AI, won the 2026 AWS Partner Network Award as Consulting Partner of the Year for Brazil. This award highlights the company's leadership in data engineering and complex infrastructure usin...
The 2026 CapitalCIO ORBIE Awards honored leading chief information officers from major organizations like Marriott International and NASA for their outstanding leadership and impact in technology. The event highlighted CIOs driving business transform...
The Fédération Internationale de l'Automobile (FIA) reported its best financial performance in 10 years for fiscal 2025, achieving an operating profit of €6.7 million, a 43% increase from the previous year, and reversing a €24 million loss in 2021. R...
Kyivstar, part of VEON Group, signed a Memorandum of Understanding with Ukraine's Ministry of Economy to develop a sovereign AI-ready data center. This initiative aims to enhance Ukraine's digital infrastructure, secure sensitive data within the coun...
Laramide Resources Ltd. held its annual and special shareholders meeting on June 26, 2026, where all proposals were approved. Shareholders elected all five management nominees to the Board of Directors and appointed RSM Canada LLP as auditors for the...
